Hormonal control of estrous cyclicity and attempted superovulation in wood bison (Bison bison athabascae).
The wood bison (Bison bison athabascae) is a threatened Canadian species that has faced extinction twice in the last 100 yr. Development of assisted reproductive technologies could help ensure the long-term propagation and genetic management of this species. The objectives of this study were to refine estrus synchronization techniques and evaluate superovulatory responses after FSH or eCG administration. In Experiment 1, females were fitted with Syncro-mate B (SMB) implants for 9 d and received an injection of either estradiol valerate (E2V; n = 9) or cloprostenol (PGF; n = 9) at implant insertion (Day-9). In Experiment 2, estrus was synchronized with SMB implants and a PGF injection of Day-9, and superovulation was attempted on Day-2 with either 2500 IU eCG (n = 5) or 400 mg Folltropin-V (n = 5). In each experiment, biosin were examined daily for estrual behavior. Ultrasonography was used during the luteal phase to detect ovulation and assess ovarian status; feces were analyzed by ELISA for immunoreactive progestogens (P) to study ovarian endocrine responses. In Experiment 1, a closer synchrony of estrus was observed between Days 2 to 4 among the PGF-treated (77.8%) than the E2V-treated (66.7%) females. Corpora lutea (CL) were detected in 55% of E2V- and PGF-treated females. In Experiment 2, neither treatment successfully induced superovulation, with only a single female per treatment producing > or = 1 CL. In both experiments, progestogen profiles were similar for each treatment (P < 0.05).
Othen
L S
LS
Toronto Zoo, Scarborough, Ontario, Canada.
Bellem
A C
AC
Gartley
C J
CJ
Auckland
K
K
King
W A
WA
Liptrap
R M
RM
Goodrowe
K L
KL
D000818:Animals; D000836:Animals, Zoo; D016164:Bison; D002170:Canada; D006063:Chorionic Gonadotropin / Q000494:pharmacology; D003008:Cloprostenol / Q000494:pharmacology; D003247:Conservation of Natural Resources; D003338:Corpus Luteum / Q000166:cytology / Q000000981:diagnostic imaging / Q000187:drug effects; D004343:Drug Implants; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004971:Estrus / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D009644:Norgestrel / Q000494:pharmacology; D006080:Ovarian Follicle / Q000166:cytology / Q000000981:diagnostic imaging / Q000187:drug effects; D013480:Superovulation / Q000187:drug effects*; D014463:Ultrasonography
D006063:Chorionic Gonadotropin; D004343:Drug Implants; D009644:Norgestrel; D003008:Cloprostenol; D004958:Estradiol; D005640:Follicle Stimulating Hormone